Inc., a privately held life sciences company marketing a novel digital molecular
barcoding technology for detecting and counting large sets of targets in biological
samples, today announced that it has increased the throughput of its nCounter®
Analysis System by expanding its multiplexing capacity to 800 gene transcripts
This additional capability allows for the high-resolution analysis of 250 additional
targets from the same amount of sample, thereby increasing the efficiency of
experiments and enabling researchers to perform studies not feasible using other
.With a growing interest in evaluating complex cellular interactions across
large numbers of biological samples, scientists are seeking solutions capable
of efficiently analyzing defined sets of targets at very high resolution. The
nCounter Analysis System is meeting this need by providing a simple workflow,
multiplexing, and direct detection and counting of individual RNA transcripts.
The application of this technology to elucidate complex biological systems in
cancer, developmental biology and cell signaling is demonstrated in a series
of recent journal publications (for more information see: www.nanostring.com/applications/publications/).
“One of the important reasons customers choose the nCounter Analysis
System is that it provides gold-standard molecular quantification in a highly
multiplexed format, and it is easier to use than other technology platforms,”
said Brad Gray, President and CEO, NanoString Technologies. “With the
new multiplexing capacity, it’s as though you are performing 800 qPCR
reactions in a single tube with only four pipetting steps.”
The nCounter Analysis System is widely used for gene signature validation,
translational research, pathway analysis, and validation of microarray and next-generation
sequencing. It includes a fully automated Prep Station, a Digital Analyzer,
the CodeSet (molecular barcodes) and all reagents needed to perform the analysis.
The nCounter System offer protocols starting with as little as 100ng of material
from a variety of specimen types including FFPE samples, cell lysate, whole-blood
lysate, and total RNA. In addition to solutions for gene expression analysis,
custom and off-the-shelf assay panels are available for miRNA profiling and
genomic copy number variation detection. More information is available at www.nanostring.com.
NanoString Technologies is a privately held life sciences company marketing
a complete solution for detecting and counting large sets of target molecules
in biological samples. The company’s nCounter® Analysis System is
the first and only technology platform to deliver highly multiplexed, direct
profiling of individual molecules in a single reaction without amplification.
The nCounter Analysis System offers a cost-effective way to easily profile hundreds
of gene transcripts, copy number variations, or miRNAs simultaneously with high
sensitivity and precision. The company’s technology enables a wide variety
of basic research and translational medicine applications, including biomarker
discovery and validation. NanoString is also developing the technology for use
in molecular diagnostics.